Bank of America is splashing out $250 million a year on weight loss drugs for its staff: ‘We see a great impact on employees,’ CEO says | Fortune0

• bond-market, Business, Business / Artificial Intelligence, Business / Big Tech, Business / Companies, Business / Computers and Software, Business / Markets, Business / Social Media, business-idea, business-insider-today, business-strategy, CoECI News, E! Insider, Energy & Environment Newsletter, Finance, Gaming News Roundup, Gear / Gear News and Events, Global, Global Precipitation, global warming, globalstar, HEALTH, Home, House, insider-picks, insider-picks-guides, insider-reviews, insider-reviews-2021, insider-today, job-market, Leadership, Markets, Markets & Festivals, News, newsletter, Newsletters, Nexstar Media Wire News, People News, Personal Finance, personal-finance, Photovogue / Editorial / News, Politics / Politics News, Property / News, Reviews, reviews-rit-ads, Security / Security News, shop, Shop Beauty, Success
• August 7, 2026

Weight-loss drugs are becoming a popular employee perk, with almost a third of workers saying they’d switch jobs to get GLP-1 coverage. Now, Bank of America is spending $250 million or more yearly on the drugs for its staffers—and CEO Brian Moynihan says the upsides are well-worth the eye-watering cost.  “What we see is a